The authors report that triple therapy retains its place in the therapeutic strategy for rheumatoid arthritis in a currently restricted economic context.
A US health economic analysis has been recently reported on one of the studies included in this review (the RACAT study). It found an incremental cost-effectiveness ratio of $521,520 per QALY per patient and the authors suggest that initiating biologic therapy without trying triple therapy first increases costs while providing minimal incremental benefit, and does not provide good value.